Novel melanoma antigen peptide and uses thereof
US-2015132329-A1 · May 14, 2015 · US
Melanoma antigen peptide and uses thereof
US9573975B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9573975-B2 |
| Application number | US-201214402803-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2012 |
| Priority date | May 22, 2012 |
| Publication date | Feb 21, 2017 |
| Grant date | Feb 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A melanoma antigen peptide having less than 40 amino acids comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5; or a fusion peptide comprising said amino acid sequence and a melanoma antigen peptide comprising the amino acids motif: TX2NDECWPX9(SEQ ID NO: 23), wherein X2 is leucine, methionine, valine, isoleucine or glutamine and X9 is alanine, valine or leucine; or a composition comprising said melanoma antigen peptide or said fusion peptide. 2. A method of treating melanoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an agent selected from the group consisting of: i) a melanoma antigen peptide according to claim 1 , ii) a fusion protein according to claim 1 , or iii) a composition according to claim 1 . 3. The method according to claim 2 wherein the patient is genotyped with HLA-DQβ1*0201 or HLA-DQβ1*0202 alleles.
Assignees
Inventors
Classifications
DNA (RNA) vaccination · CPC title
Fusion polypeptide · CPC title
- C07K14/4748Primary
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
- C07K7/08Primary
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Cancer antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9573975B2 cover?
- The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in pat…
- Who is the assignee on this patent?
- Labarriere Nathalie, Lang François, Bobinet Mathilde, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4748. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).